PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma

Published on Aug 1, 2018in The Journal of Nuclear Medicine7.887
· DOI :10.2967/JNUMED.117.205054
Stephen A. Jannetti6
Estimated H-index: 6
(CUNY: City University of New York),
Giuseppe Carlucci27
Estimated H-index: 27
(NYU: New York University)
+ 16 AuthorsThomas Reiner39
Estimated H-index: 39
(Cornell University)
: The DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP-1) is overexpressed in glioblastoma, with overall low expression in healthy brain tissue. Paired with the availability of specific small molecule inhibitors, PARP-1 is a near-ideal target to develop novel radiotherapeutics to induce DNA damage and apoptosis in cancer cells, while sparing healthy brain tissue. Methods: We synthesized an 131I-labeled PARP-1 therapeutic and investigated its pharmacology in vitro and in vivo. A subcutaneous tumor model was used to quantify retention times and therapeutic efficacy. A potential clinical scenario, intratumoral convection-enhanced delivery, was mimicked using an orthotopic glioblastoma model combined with an implanted osmotic pump system to study local administration of 131I-PARPi (PARPi is PARP inhibitor). Results:131I-PARPi is a 1(2H)-phthalazinone, similar in structure to the Food and Drug Administration-approved PARP inhibitor AZD-2281. In vitro studies have shown that 131I-PARPi and AZD-2281 share similar pharmacologic profiles. 131I-PARPi delivered 134.1 cGy/MBq intratumoral injected activity. Doses to nontarget tissues, including liver and kidney, were significantly lower. Radiation damage and cell death in treated tumors were shown by p53 activation in U87-MG cells transfected with a p53-bioluminescent reporter. Treated mice showed significantly longer survival than mice receiving vehicle (29 vs. 22 d, P < 0.005) in a subcutaneous model. Convection-enhanced delivery demonstrated efficient retention of 131I-PARPi in orthotopic brain tumors, while quickly clearing from healthy brain tissue. Conclusion: Our results demonstrate 131I-PARPi's high potential as a therapeutic and highlight PARP's relevance as a target for radionuclide therapy. Radiation plays an integral role in brain tumor therapy, and radiolabeled PARP therapeutics could ultimately lead to improvements in the standard of care.
Figures & Tables
📖 Papers frequently viewed together
49 Citations
21 Citations
46 Citations
#1Brandon Carney (CUNY: City University of New York)H-Index: 9
#2Susanne Kossatz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 15
Last. Thomas Reiner (Cornell University)H-Index: 39
view all 10 authors...
Insufficient chemotherapy response and rapid disease progression remain concerns for small-cell lung cancer (SCLC). Oncologists rely on serial CT scanning to guide treatment decisions, but this cannot assess in vivo target engagement of therapeutic agents. Biomarker assessments in biopsy material do not assess contemporaneous target expression, intratumoral drug exposure, or drug-target engagement. Here, we report the use of PARP1/2-targeted imaging to measure target engagement of PARP inhibitor...
44 CitationsSource
#1Komal Anjum (ZJU: Zhejiang University)H-Index: 10
#2Bibi Ibtesam Shagufta (Kohat University of Science and Technology)H-Index: 4
Last. Syed Shams ul Hassan (ZJU: Zhejiang University)H-Index: 8
view all 8 authors...
Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic a...
86 CitationsSource
#1Balázs Murnyák (University of Debrecen)H-Index: 6
#2Mahan C. Kouhsari (University of Debrecen)H-Index: 2
Last. Tibor Hortobágyi (University of Debrecen)H-Index: 87
view all 7 authors...
// Balazs Murnyak 1 , Mahan C. Kouhsari 1 , Rotem Hershkovitch 1 , Bernadette Kalman 2, 3 , Gyorgy Marko-Varga 4 , Almos Klekner 5 and Tibor Hortobagyi 1, 6 1 Division of Neuropathology, Institute of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary 2 Institute of Diagnostics, Faculty of the Health Sciences, University of Pecs, Pecs, Hungary 3 Molecular Pathology Unit, Markusovszky Teaching Hospital, Szombathely, Hungary 4 Division of Clinical Protein Science & Imaging, D...
18 CitationsSource
#1Brandon Carney (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
#2Susanne Kossatz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 15
Last. Thomas Reiner (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 39
view all 3 authors...
: The poly(adenosine diphosphate-ribose)polymerase (PARP) family of enzymes is an important factor in the cellular DNA damage response and has gained much attention for its role in many diseases, particularly cancer. Targeted molecular imaging of PARP using fluorescent or radiolabeled tags has followed on the success of therapeutic inhibitors and gained momentum over the past few years. This review covers PARP imaging from the very first imaging agents up to the current state of the technology, ...
49 CitationsSource
#1Susanne Kossatz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 15
#2Brandon Carney (CUNY: City University of New York)H-Index: 9
Last. Thomas Reiner (Cornell University)H-Index: 39
view all 12 authors...
Diffuse intrinsic pontine glioma (DIPG) is a childhood brainstem tumor with a universally poor prognosis. Here, we characterize a positron emission tomography (PET) probe for imaging DIPG in vivo . In human histological tissues, the probes target, PARP1, was highly expressed in DIPG compared to normal brain. PET imaging allowed for the sensitive detection of DIPG in a genetically engineered mouse model, and probe uptake correlated to histologically determined tumor infiltration. Imaging with the...
15 CitationsSource
#1John Bianco (UCL: Université catholique de Louvain)H-Index: 9
#2Chiara Bastiancich (UCL: Université catholique de Louvain)H-Index: 11
Last. Fabienne Danhier (UCL: Université catholique de Louvain)H-Index: 26
view all 6 authors...
Although brain tumours have been documented and recorded since the nineteenth century, 2016 marked 90 years since Percival Bailey and Harvey Cushing coined the term “glioblastoma multiforme”. Since that time, although extensive developments in diagnosis and treatment have been made, relatively little improvement on prognosis has been achieved. The resilience of GBM thus makes treating this tumour one of the biggest challenges currently faced by neuro-oncology. Aggressive and robust development, ...
32 CitationsSource
#1James C. Knight (University of Oxford)H-Index: 15
#2Sofia Koustoulidou (University of Oxford)H-Index: 3
Last. Bart Cornelissen (University of Oxford)H-Index: 23
view all 3 authors...
DNA integrity is constantly challenged by endogenous and exogenous factors that can alter the DNA sequence, leading to mutagenesis, aberrant transcriptional activity, and cytotoxicity. Left unrepaired, damaged DNA can ultimately lead to the development of cancer. To overcome this threat, a series of complex mechanisms collectively known as the DNA damage response (DDR) are able to detect the various types of DNA damage that can occur and stimulate the appropriate repair process. Each DNA damage ...
29 CitationsSource
#1Redmond-Craig Anderson (UPenn: University of Pennsylvania)H-Index: 3
#2Mehran Makvandi (UPenn: University of Pennsylvania)H-Index: 14
Last. Robert H. Mach (UPenn: University of Pennsylvania)H-Index: 60
view all 7 authors...
Abstract Background PARP inhibitors (PARPi) have the potential to impact cancer therapy in a selective patient population; however, despite current patient selection methods clinical trials have shown mixed response rates. It is therefore clinically useful to determine which patients will respond prior to receiving PARPi therapy. One essential biomarker is to measure the level of PARP enzyme expression in tumors. Small molecule radiotracers have been developed to accurately quantify PARP-1 expre...
15 CitationsSource
#1Yves Pommier (NIH: National Institutes of Health)H-Index: 146
#2Mark J. O'Connor (AstraZeneca)H-Index: 58
Last. Johann S. de Bono (National Health Service)H-Index: 124
view all 3 authors...
Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP “trapping” and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
285 CitationsSource
#1Aparajitha Vaidyanathan (Dund.: University of Dundee)H-Index: 2
#2Lynne Sawers (Dund.: University of Dundee)H-Index: 2
Last. Gillian Smith (Dund.: University of Dundee)H-Index: 49
view all 8 authors...
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
126 CitationsSource
Cited By20
#1Thomas C. Wilson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Giacomo Pirovano (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
Last. Naga Vara Kishore Pillarsetty (Cornell University)H-Index: 8
view all 12 authors...
Despite Auger electrons being highly appealing due to their short-range and high linear energy transfer to surrounding tissues, the progress in the field has been limited due to the challenge in delivering a therapeutic dose within the close proximity of cancer cell's DNA. Here, we demonstrate that the PARP inhibitor 123I-MAPi is a viable agent for the systemic administration and treatment of p53 mutant cancers. Significantly, minimal off-site toxicity was observed in mice administered with up t...
#1Giacomo Pirovano (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
#2Alvaro A. Ordonez (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 18
Last. Naga Vara Kishore Pillarsetty (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 8
view all 6 authors...
PURPOSE: Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus 2019 disease (COVID-19), poses a serious risk to humanity and represents a huge challenge for healthcare systems worldwide. Since the early days of the COVID-19 pandemic, it has been evident that adequate testing is an essential step in limiting and controlling the spread of SARS-CoV-2. Here, we present an accurate, inexpensive, scalable, portable, and rapid detection kit to directly dete...
#1Dong ZhouH-Index: 23
#2Huaping ChenH-Index: 1
Last. Jinbin XuH-Index: 31
view all 8 authors...
Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme in the DNA repair process and the target of several FDA-approved inhibitors. Several of these inhibitors have been radiolabeled for non-invasive imaging of PARP-1 expression or targeted radiotherapy of PARP-1 expressing tumors. In particular, derivatives of olaparib and rucaparib, which have reduced trapping potency by PARP-1 compared to talazoparib, have been radiolabeled for these purposes. Here, we report the first radiosynthesis of...
#2Kel Vin Tan (HKU: University of Hong Kong)H-Index: 4
Last. Bart Cornelissen (University of Oxford)H-Index: 23
view all 3 authors...
Targeting of PARP enzymes has emerged as an effective therapeutic strategy to selectively target cancer cells with deficiencies in homologous recombination signaling. Currently used to treat BRCA-mutated cancers, PARP inhibitors (PARPi) have demonstrated improved outcome in various cancer types as single agents. Ongoing efforts have seen the exploitation of PARPi combination therapies, boosting patient responses as a result of drug synergisms. Despite great successes using PARPi therapy, selecti...
3 CitationsSource
#1Julie BolcaenH-Index: 8
#2Janke Kleynhans (University of Pretoria)H-Index: 2
Last. Thomas Ebenhan (University of Pretoria)H-Index: 13
view all 8 authors...
Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma (GB) remains a challenge. The current survival rate of GB averages one year, even with an optimal standard of care. However, the future promises efficient patient-tailored treatments, including targeted radionuclide therapy (TRT). Advances in radiopharmaceutical development have unlocked the possibility to assess disease at the molecular level allowing individual diagnosis. This leads to the possibility...
1 CitationsSource
#1V. Behrana Jensen (University of Texas MD Anderson Cancer Center)H-Index: 4
#1V. Behrana JensenH-Index: 2
Last. Suzanne CraigH-Index: 8
view all 2 authors...
#1Laura Bruton (UM: University of Michigan)
#2Peter Scott (UM: University of Michigan)H-Index: 20
Last. Peter J. H. Scott (UM: University of Michigan)H-Index: 24
view all 2 authors...
1 CitationsSource
#1Aladdin Riad (UPenn: University of Pennsylvania)H-Index: 8
#2Sarah B. Gitto (UPenn: University of Pennsylvania)H-Index: 5
Last. Mehran Makvandi (UPenn: University of Pennsylvania)H-Index: 14
view all 11 authors...
Theranostics are emerging as a pillar of cancer therapy that enable the use of single molecule constructs for diagnostic and therapeutic application. As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 can be safely targeted with Auger emitters to induce DNA damage in tumors. Here, we investigated a radioiodinated PARP inhibitor, [125I]KX1, and show drug target specific DNA damage and subsequent killin...
1 CitationsSource
#1Ramya Ambur Sankaranarayanan (RWTH Aachen University)H-Index: 2
#2Susanne Kossatz (TUM: Technische Universität München)H-Index: 15
Last. Felix M. Mottaghy (RWTH Aachen University)H-Index: 72
view all 6 authors...
The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certain cancers such as gBRCAmut breast and ovarian cancers has led to its exploitation as a target. The overexpression of PARP1 in several types of cancer further evoked interest in its use as an imaging target. While PARP1-targeted inhibitors have fast ...
6 CitationsSource
#1Thomas C. Wilson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#1Thomas C. Wilson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Giacomo Pirovano (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
view all 6 authors...
Purpose:123I-MAPi, a novel PARP1-targeted Auger radiotherapeutic has shown promising results in pre-clinical glioma model. Currently 123I-MAPi is synthesized using multistep synthesis that results in modest yields and low molar activities that limits the ability to translate this technology for human studies where high doses are administered. Therefore, new methods are needed to synthesize 123I-MAPi in high activity yields and improved molar activities to facilitate clinical translation and mult...
3 CitationsSource